ImageneBio Inc
NASDAQ:IMABiotechnology
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
Volume 0.00M
Average 0.35M
IMA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
ImageneBio IncNASDAQ: IMA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 106.9% from a year ago
Cash & equivalents stood at $76.05M at the end of Q1 FY2026, up 106.9% from a year earlier and up 117.5% from the prior quarter. Over 3 fiscal years it compounded at -16.4% a year.
Context
- Cash & equivalents amounted to 55.6% of total assets at the end of Q1 FY2026, up 27.5 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +106.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 34.97M USD
- Year-over-year change
- -11.2%
- 4-year CAGR
- -37.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.97M | -11.2% |
| FY2024 | 2024-12-31 | 39.39M | -67.1% |
| FY2023 | 2023-12-31 | 119.89M | +100.1% |
| FY2022 | 2022-12-31 | 59.92M | -74.2% |
| FY2021 | 2021-12-31 | 232.22M | — |
Cash & Equivalents vs competitors
How IMA compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +106.9% is the 2nd highest of 9, against a peer median of -35.0%.
- Cash & equivalents amounts to 55.6% of total assets for IMA, versus a peer median of 36.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $94.06M USD | +345.0% | -33.6% | 41.7% | |
| Mar 2026 | $90.42M USD | +48.5% | +4.6% | 88.5% | |
IMAImageneBio Inc | Mar 2026 | $76.05M USD | +106.9% | -16.4% | 55.6% |
| Mar 2026 | $73.68M USD | -30.6% | +7.1% | 30.4% | |
| Mar 2026 | $54.53M USD | -39.0% | +23.0% | 92.6% | |
| Dec 2025 | $38.35M USD | -51.0% | -21.4% | 68.4% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $34.43M USD | -65.9% | +217.7% | 31.4% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $20.96M USD | -31.1% | -36.1% | 19.8% |
| Mar 2026 | €15.01M EUR | -68.3% | -0.5% | 30.7% | |
| Peer median (excluding IMA) | — | -35.0% | +2.0% | 36.5% | |
Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 232.22M | 59.92M | 119.89M | 39.39M | 34.97M |
| Short-term Investments | 0 | 97.03M | 55.57M | 84.99M | 40.82M |
| Net Receivables | 0 | 0 | 0 | 0 | 1.3M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 629K | 964K | 1.15M | 2.78M | 63.21M |
| Total Current Assets | 236.52M | 160.01M | 178.66M | 127.17M | 140.29M |
| Property, Plant & Equipment (Net) | 8.98M | 8.46M | 8.02M | 4.23M | 790K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 2.39M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 3.79M | 5.41M | 10.11M | 11.9M |
| Total Non-current Assets | 11.36M | 12.25M | 13.43M | 14.34M | 12.69M |
| Total Assets | 247.88M | 172.26M | 192.09M | 141.51M | 152.98M |
| Account Payables | 2.38M | 2.09M | 2.07M | 897K | 1.44M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 17.1M | 9.16M | 0 | 0 | 0 |
| Other Current Liabilities | 2.84M | 5.11M | 3.4M | 1.75M | 7.53M |
| Total Current Liabilities | 27.19M | 21.5M | 14.21M | 10.78M | 11.23M |
| Long-term Debt | 0 | 0 | 0 | 0 | 7.02M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 7.68M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 950K | 1.06M | 870K |
| Total Non-current Liabilities | 12.81M | 3.79M | 8.13M | 4.8M | 8.6M |
| Total Liabilities | 40M | 25.29M | 22.34M | 15.58M | 19.84M |
| Common Stock | 36K | 36K | 48K | 48K | 11K |
| Retained Earnings | (145.45M) | (214.22M) | (282.39M) | (331.62M) | (230.05M) |
| Accumulated OCI | 0 | (763K) | (48K) | 68K | 87K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 207.88M | 146.97M | 169.76M | 125.93M | 133.14M |
| Total Debt | 6.99M | 5.69M | 10.74M | 7.52M | 10M |
| Net Debt | (225.23M) | (54.23M) | (109.16M) | (31.87M) | (24.97M) |
ImageneBio Inc
NASDAQ:IMA
Intrinsic Alpha fair value
Locked
Current Price
$4.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.